Analysed MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading
15-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
13-04-2026
yahoo.com
We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely
07-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
06-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
02-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rising Sharply in Wednesday Trading
01-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for Week
20-03-2026
yahoo.com
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
19-03-2026
yahoo.com
What is the current price of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)?
The current price of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) is $0.3376.
MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) absolute price change since previous trading day?
The absolute price change of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) since the previous trading day is $0.0113.
MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) percentage price change since previous trading day?
The percentage price change of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) since the previous trading day is 3.4631%.
What is the most recent average sentiment score for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)?
The most recent average sentiment score for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) is 30 out of 100.
What is the most recent average sentiment for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)?
The most recent sentiment for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) is .
SEC-8K** Filing Available For MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.